Changeflow GovPing Healthcare & Life Sciences Probiotic Preparation Containing Akk11 Strain f...
Routine Notice Added Final

Probiotic Preparation Containing Akk11 Strain for Calcium Absorption

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260109939A1, filed June 19, 2024 under application no. 18995236, disclosing a probiotic preparation combining Akkermansia muciniphila Akk11 strain and Bifidobacterium breve BBr16 strain designed to synergistically enhance calcium absorption by improving intestinal health and strengthening the absorption capacity of the intestinal wall. The application claims the preparation can promote serum calcium and phosphorus levels, restore normal electrolyte levels, and reduce calcium loss in bones to stabilize bone structure and function. This is the initial publication of the patent application — no patent has yet been granted.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 227 changes logged to date.

What changed

USPTO published patent application US20260109939A1 for a probiotic preparation combining Akkermansia muciniphila Akk11 and Bifidobacterium breve BBr16 strains, claiming synergistic enhancement of calcium absorption through improved intestinal health and enhanced intestinal wall absorption capacity. The application further claims promotion of serum calcium and phosphorus levels, restoration of normal electrolyte balance, and reduction of calcium loss from bones. CPC classifications include C12N 1/20 and A61P 3/14, with six named inventors including Shuguang Fang and Jianguo Zhu. No patent has been granted — this is a published application stage document.

Functional food manufacturers, dietary supplement producers, and pharmaceutical companies developing calcium-related or gut-health products should monitor this filing as it matures through the examination process. If granted, the broad combinatorial claims covering Akk11 with BBr16 for calcium absorption could affect freedom-to-operate analyses for competing probiotic and supplement products targeting bone health or mineral absorption.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PROBIOTIC PREPARATION CONTAINING AKK11 STRAIN FOR PROMOTING CALCIUM ABSORPTION AND USE THEREOF

Application US20260109939A1 Kind: A1 Apr 23, 2026

Inventors

Shuguang FANG, Yao DONG, Jiayue GU, Zhiyi WU, Zhonghui GAI, Jianguo ZHU

Abstract

Provided are a probiotic preparation containing an Akk11 strain for promoting calcium absorption and a use thereof, and the probiotic preparation for promoting calcium absorption includes an Akkermansia muciniphila Akk11 strain and a Bifidobacterium breve BBr16 strain. The present application developed a novel compounding method for probiotics, and found potential interactions between the Akk11 strain and BBr16 strain that these two strains can cooperate with each other to synergistically enhance the effect of promoting calcium absorption, specifically manifested in: the overall metabolism ability of calcium can be improved through the improvement of intestinal health and the enhancement of the absorption capacity of the intestinal wall; the serum calcium level and phosphorus content can be promoted and restore a normal electrolyte level; and the loss of calcium in bones can be effectively reduced, thereby stabilizing the structure and function of the bones.

CPC Classifications

C12N 1/20 A61P 3/14 A61K 2035/11 C12R 2001/01

Filing Date

2024-06-19

Application No.

18995236

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260109939A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Biotech research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!